146 related articles for article (PubMed ID: 27416058)
1. Pregnancy outcomes after fetal exposure to antithyroid medications or levothyroxine.
Schurmann L; Hansen AV; Garne E
Early Hum Dev; 2016 Oct; 101():73-7. PubMed ID: 27416058
[TBL] [Abstract][Full Text] [Related]
2. The effect of maternal exposure to psychosocial job strain on pregnancy outcomes and child development.
Larsen AD
Dan Med J; 2015 Feb; 62(2):. PubMed ID: 25634513
[TBL] [Abstract][Full Text] [Related]
3. Maternal Thyroid Function, Use of Antithyroid Drugs in Early Pregnancy, and Birth Defects.
Andersen SL; Knøsgaard L; Olsen J; Vestergaard P; Andersen S
J Clin Endocrinol Metab; 2019 Dec; 104(12):6040-6048. PubMed ID: 31408173
[TBL] [Abstract][Full Text] [Related]
4. Gestational thyrotoxicosis, antithyroid drug use and neonatal outcomes within an integrated healthcare delivery system.
Lo JC; Rivkees SA; Chandra M; Gonzalez JR; Korelitz JJ; Kuzniewicz MW
Thyroid; 2015 Jun; 25(6):698-705. PubMed ID: 25747892
[TBL] [Abstract][Full Text] [Related]
5. Fetal Exposure to Montelukast and Congenital Anomalies: A Population Based Study in Denmark.
Cavero-Carbonell C; Vinkel-Hansen A; Rabanque-Hernández MJ; Martos C; Garne E
Birth Defects Res; 2017 Apr; 109(6):452-459. PubMed ID: 28398707
[TBL] [Abstract][Full Text] [Related]
6. The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy.
Namazy J; Cabana MD; Scheuerle AE; Thorp JM; Chen H; Carrigan G; Wang Y; Veith J; Andrews EB
J Allergy Clin Immunol; 2015 Feb; 135(2):407-12. PubMed ID: 25441639
[TBL] [Abstract][Full Text] [Related]
7. Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study.
Andersen SL; Olsen J; Wu CS; Laurberg P
J Clin Endocrinol Metab; 2013 Nov; 98(11):4373-81. PubMed ID: 24151287
[TBL] [Abstract][Full Text] [Related]
8. Treatment of graves' disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation.
Yoshihara A; Noh J; Yamaguchi T; Ohye H; Sato S; Sekiya K; Kosuga Y; Suzuki M; Matsumoto M; Kunii Y; Watanabe N; Mukasa K; Ito K; Ito K
J Clin Endocrinol Metab; 2012 Jul; 97(7):2396-403. PubMed ID: 22547422
[TBL] [Abstract][Full Text] [Related]
9. Major congenital anomalies in a Danish region.
Garne E; Hansen AV; Birkelund AS; Andersen AM
Dan Med J; 2014 Jun; 61(6):A4825. PubMed ID: 24947618
[TBL] [Abstract][Full Text] [Related]
10. Risk of adverse fetal outcomes following administration of a pandemic influenza A(H1N1) vaccine during pregnancy.
Pasternak B; Svanström H; Mølgaard-Nielsen D; Krause TG; Emborg HD; Melbye M; Hviid A
JAMA; 2012 Jul; 308(2):165-74. PubMed ID: 22782418
[TBL] [Abstract][Full Text] [Related]
11. Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations: population based European register study.
Graner S; Svensson T; Beau AB; Damase-Michel C; Engeland A; Furu K; Hviid A; Håberg SE; Mølgaard-Nielsen D; Pasternak B; Kieler H
BMJ; 2017 Feb; 356():j629. PubMed ID: 28246106
[No Abstract] [Full Text] [Related]
12. A Retrospective Cohort Study of Birth Outcomes in Neonates Exposed to Naltrexone in Utero: A Comparison with Methadone-, Buprenorphine- and Non-opioid-Exposed Neonates.
Kelty E; Hulse G
Drugs; 2017 Jul; 77(11):1211-1219. PubMed ID: 28536981
[TBL] [Abstract][Full Text] [Related]
13. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
14. Use of thyroid hormones in relation to pregnancy: a Danish nationwide cohort study.
Gidén K; Andersen JT; Torp-Pedersen AL; Enghusen Poulsen H; Torp-Pedersen C; Jimenez-Solem E
Acta Obstet Gynecol Scand; 2015 Jun; 94(6):591-7. PubMed ID: 25732102
[TBL] [Abstract][Full Text] [Related]
15. Perinatal outcomes of a pregnancy complicated by cancer, including neonatal follow-up after in utero exposure to chemotherapy: results of an international registry.
Cardonick E; Usmani A; Ghaffar S
Am J Clin Oncol; 2010 Jun; 33(3):221-8. PubMed ID: 19745695
[TBL] [Abstract][Full Text] [Related]
16. Pregnancy and fetal outcomes following paternal exposure to glatiramer acetate.
Kaplan S; Dragut CF; Ghimpeteanu A
Curr Med Res Opin; 2024 May; 40(5):821-825. PubMed ID: 38577712
[TBL] [Abstract][Full Text] [Related]
17. Risk of adverse perinatal outcomes with antithyroid treatment during pregnancy: a nationwide population-based study.
Chen CH; Xirasagar S; Lin CC; Wang LH; Kou YR; Lin HC
BJOG; 2011 Oct; 118(11):1365-73. PubMed ID: 21624036
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of thyrotoxicosis, antithyroid medication use, and complications among pregnant women in the United States.
Korelitz JJ; McNally DL; Masters MN; Li SX; Xu Y; Rivkees SA
Thyroid; 2013 Jun; 23(6):758-65. PubMed ID: 23194469
[TBL] [Abstract][Full Text] [Related]
19. Maternal thyroid function in the first twenty weeks of pregnancy and subsequent fetal and infant development: a prospective population-based cohort study in China.
Su PY; Huang K; Hao JH; Xu YQ; Yan SQ; Li T; Xu YH; Tao FB
J Clin Endocrinol Metab; 2011 Oct; 96(10):3234-41. PubMed ID: 21832110
[TBL] [Abstract][Full Text] [Related]
20. The safety of sumatriptan and naratriptan in pregnancy: what have we learned?
Cunnington M; Ephross S; Churchill P
Headache; 2009; 49(10):1414-22. PubMed ID: 19804390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
